MyoCell: Preliminary Phase II/III data

Data from 20 patients enrolled in Part 1 of the double-blind, international, pivotal Phase II/III MARVEL trial showed that MyoCell increased average 6-minute walk distance (6MWD) by >91 meters vs. a d...